Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Not yet recruiting, industry sponsors, Psychiatry, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed907
11 trials
Showing 1 to 11, recently updated first.
- Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese AdultsPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07911787 · 476 participants (planned) · Start Nov 4, 2026 · Primary completion Jan 24, 2029
Drug: HS-10380; Aripiprazole and 1 more · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Shanghai, China
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderPivotal-lookingNot yet recruiting
Intra-Cellular Therapies, Inc.Industry
NCT07747389 · 585 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 20, 2029
Drug: Lumateperone; Placebo · For: Depressive Disorder, Major
- Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant MonotherapyPivotal-lookingNot yet recruiting
Bukwang PharmaceuticalIndustry
NCT07781293 · 364 participants (planned) · Start Sep 28, 2026 · Primary completion Oct 2027
Drug: Lurasidone; Placebo and 1 more · For: Major Depressive Disorder (MDD); Major Depressive Disorder With Psychotic Features
- A Study to Evaluate the Long-term Safety of HS-10380 in Patients With SchizophreniaPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07759869 · 500 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 31, 2028
Drug: HS-10380 · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Beijing, China
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With SchizophreniaPivotal-lookingNot yet recruiting
Bostal Drug Delivery Co., LtdIndustry
NCT07742280 · 16 participants (planned) · Start Aug 2026 · Primary completion Aug 2027
Drug: Brexpiprazole for ER injection, 45 mg; Brexpiprazole for ER injection, 100 mg · For: Schizophrenia
- A Study of KH607 as Monotherpy in Adults Participants With Major Depressive DisorderPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07741240 · 232 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: KH607 tablets; placebo and 1 more · For: Major Depressive Disorder (MDD)
- Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive DisorderPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07741331 · 326 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: KH607 tablets; Vortioxetine Hydrobromide Tablets and 1 more · For: Major Depressive Disorder (MDD)
- A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With SchizophreniaPivotal-lookingNot yet recruiting
Bostal Drug Delivery Co., LtdIndustry
NCT07722728 · 84 participants (planned) · Start Aug 2026 · Primary completion Aug 2027
Drug: 30 mg B2227; 70 mg B2227 and 5 more · For: Schizophrenia
- A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHDPivotal-lookingNot yet recruiting
Alvogen KoreaIndustry
NCT07678827 · 156 participants (planned) · Start Jul 2026 · Primary completion Sep 2027
Drug: AK-D101; Placebo · For: Attention Deficit Hyperactivity Disorder; Attention-Deficit / Hyperactivity Disorder; ADHD
Sites: Seoul, South Korea
- A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe DepressionPivotal-lookingNot yet recruiting
Tasly Pharmaceutical Group Co., LtdIndustry
NCT07485595 · 180 participants (planned) · Start Apr 30, 2026 · Primary completion Dec 31, 2026
Drug: Placebo group; JS1-1-01 low-dose group and 1 more · For: Depression
Sites: Beijing, China
- A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute SchizophreniaPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT06589817 · 376 participants (planned) · Start Oct 2024 · Primary completion Jun 2026
Drug: Hydrochloride Carliprazine capsules; Aripiprazole tablets · For: Acute Schizophrenia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.